TISIDB

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00498 FHA domain
Function	Down-regulates NF-kappa-B signaling by competing with RELA for CREBBP/EP300 binding. Involved in the microRNA (miRNA) biogenesis. May be involved in cyclin-D1/CCND1 mRNA stability through the SNARP complex which associates with both the 3'end of the CCND1 gene and its mRNA.

> Gene Ontology [ TOP ]
Biological Process	GO:0006417 regulation of translation GO:0006626 protein targeting to mitochondrion GO:0006839 mitochondrial transport GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0010608 posttranscriptional regulation of gene expression GO:0010821 regulation of mitochondrion organization GO:0010822 positive regulation of mitochondrion organization GO:0016441 posttranscriptional gene silencing GO:0016458 gene silencing GO:0017148 negative regulation of translation GO:0031047 gene silencing by RNA GO:0031050 dsRNA fragmentation GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0033157 regulation of intracellular protein transport GO:0034248 regulation of cellular amide metabolic process GO:0034249 negative regulation of cellular amide metabolic process GO:0035194 posttranscriptional gene silencing by RNA GO:0035195 gene silencing by miRNA GO:0035196 production of miRNAs involved in gene silencing by miRNA GO:0040029 regulation of gene expression, epigenetic GO:0043331 response to dsRNA GO:0051222 positive regulation of protein transport GO:0070585 protein localization to mitochondrion GO:0070918 production of small RNA involved in gene silencing by RNA GO:0071359 cellular response to dsRNA GO:0071407 cellular response to organic cyclic compound GO:0072655 establishment of protein localization to mitochondrion GO:0090316 positive regulation of intracellular protein transport GO:1903214 regulation of protein targeting to mitochondrion GO:1903533 regulation of protein targeting GO:1903747 regulation of establishment of protein localization to mitochondrion GO:1903749 positive regulation of establishment of protein localization to mitochondrion GO:1903829 positive regulation of cellular protein localization GO:1903955 positive regulation of protein targeting to mitochondrion GO:1904951 positive regulation of establishment of protein localization
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SNIP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SNIP1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29634978	Squamous Cell Carcinoma	Inhibit immunity	SNIP1 overexpression, unmethylated TWIST1, smoking, and poorly-differentiated tumors were predictive for PD-L1 overexpression.

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SNIP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SNIP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.088	0.564
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.159	0.897
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.263	0.75
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.345	0.181
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.05	0.975
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.719	0.725
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.054	0.853
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.007	0.996
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.107	0.938
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.13	0.87
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.419	0.707
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.114	0.0244

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SNIP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SNIP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SNIP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SNIP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SNIP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SNIP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SNIP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SNIP1
Name	Smad nuclear interacting protein 1
Aliases	PMRED; FHA domain-containing protein SNIP1; Smad nuclear-interacting protein 1
Chromosomal Location	1p34.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SNIP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SNIP1